Skip to main content

Table 6 Tumor response

From: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis

 

Lenvatinib (N, %)

Sorafenib (N, %)

p-value

CR

2 (4.5%)

3 (3.4%)

 

PR

6 (13.6%)

1 (1.1%)

 

SD

26 (59.1%)

38 (43.2%)

 

PD

10 (22.7%)

44 (50.0%)

 

Not assessed

0 (0%)

2 (2.3%)

 

ORR

18.2%

4.5%

0.020

DCR

77.3%

47.7%

0.001

  1. Data are presented as number (%)
  2. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us